Hi Westhot,in Broad terms PYC treats single gene mutation...

Hi Westhot,

in Broad terms PYC treats single gene mutation diseases. It differentiates itself from others by using a cell penetrating peptide to cross the cell membrane this allows a marked reduction in required dose and markedly reduces any possibility of toxicity. It attaches this to a drug targets to a specific gene mutation. This amplifies the production of protein at the RNA level allowing the deficient protein to be replaced. Ongoing treatments are required proposed at 3 monthly intervals.

These types of therapies have a high probability of clinical success and this is enhanced by PYC’s preclinical human tissue trials. E.g. the “retina in a dish.

There are 4 drugs that have been disclosed and there is also a development pipeline which we are not privy to. Three in or very near clinical stage trials.

1. Retinitis Pigmentosa the most advanced. It has been through Single Ascending Dose, now entering multiple ascending dose. They tend to release data every few months when they test the vision. Probably due one in the next few weeks.

2. Adult Dominant Optic atrophy I believe we are waiting for an announcement saying the first human is dosed. Potential for multiple phase II trials different disease this one drug including glaucoma.

3. Adult dominant polycystic kidney disease. Going through FDA approval for First in Human. Waiting that announcement. (This is the biggest 12 billion market US)

4. Phelan Mcdermoid Syndrome. A bit further back going in in the background.

With regards to funding. A cap raise is possible. The option of selling one of the smaller market size drugs I.e. RP has also been raised. No one here seems too bothered. After the last raise the share price spiked. Probably because there was increased confidence the pipeline could be funded. Either option is good.

Eagle